Latest Information

Neutrophil-to-Lymphocyte Ratio May Be Associated With mRCC Outcomes

April 26, 2012

Two recent studies have reported on the possible utility of assessing pre-treatment neutrophil-to-lymphocyte ratio (NLR) as a prognostic factor in mRCC.

Tandutinib Not Effective For mRCC

April 26, 2012

A small phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases (FLT3), has concluded that the novel agent has no clinical activity and excessive toxicity, and should not be developed further for mRCC.

Low Recurrence And Cancer Death Rates Associated With Kidney Cancer Subtype

March 31, 2012

Patients with papillary renal cell carcinoma, the second most common kidney cancer subtype, face a low risk of tumour recurrence and cancer-related death after surgery.

Pfizer Files For FDA Approval Of Kidney Cancer Treatment

The AP (6/29) reports that "Pfizer Inc. said Tuesday it filed for marketing approval of its drug candidate axitinib as a treatment for advanced renal cell carcinoma, the most common type of kidney cancer." Pfizer "is seeking Food and Drug Administration approval based on studies that showed patients who were treated with axitinib lived longer without disease progression than patients treated with Nexavar."

Filed Under: Uncategorized